Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06182124 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

A Phase 1 study of Pneumococcal Disease, sponsored by Pfizer.

Active
Registry status
Phase 1
Development phase
558
Enrollment target
18
Study locations

NCT06182124 is a Phase 1 study of Pneumococcal Disease that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 558 participants, above the 401-participant average among 3 other Pneumococcal Disease trials with a reported enrollment target (39% higher). The trial reports 18 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06182124, a Phase 1 study of Pneumococcal Disease, is active but no longer recruiting, sponsored by Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
558 participants
Enrollment target
18
Study locations

Study Summary

The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease. This study will happen in 4 stages: Stage 1 is seeking participants who are between 18 years to 49 years of age. The participants will receive 1 of 2 pneumococcal vaccine candidates (different formulations) or 20vPnC (Prevnar 20) as a single shot given into the upper arm muscle. Stage 2 will begin after participants have completed Stage 1, and a pneumococcal vaccine candidate has been decided. Stage 2 is seeking participants who are adults 50 years of age and older. The participants will receive the chosen pneumococcal vaccine candidate from Stage 1 or 20vPnC (Prevnar 20). The vaccines will be given as a single shot into the upper arm muscle. Stage 3 is seeking participants who are adults 50 years of age and older. The participants will receive the chosen pneumococcal vaccine candidate from Stage 1 or a licensed pneumococcal comparator vaccine. The vaccines will be given as a single shot into the upper arm muscle. Stage 4 is seeking participants who are adults 50 years of age and older. The participants will receive either one of three pneumococcal vaccine candidates or one of two licensed pneumococcal comparator vaccines. The vaccines will be given as a single shot into the upper arm muscle. Participants will take part in this study for about 6 months for Stage 1, Stage 3, and Stage 4 and 12 months for Stage 2. During this time participants will have from 2 to 4 clinic visits and 1 phone visit. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during these clinic visits.

Conditions Studied

Pneumococcal Disease

Interventions

  • BIOLOGICAL 20-valent pneumococcal conjugate vaccine (20vPnC)
  • BIOLOGICAL Multivalent Pneumococcal Vaccine - Formulation 1
  • BIOLOGICAL Multivalent Pneumococcal Vaccine - Formulation 2
  • BIOLOGICAL Licensed pneumococcal comparator vaccine
  • BIOLOGICAL Multivalent Pneumococcal Vaccine - Formulation 3

Study Locations (18)

Texas

  • Headlands Horizons LLC - Brownsville
  • DM Clinical Research- Cyfair - Houston
  • Clinical Trials of Texas, LLC dba Flourish Research - San Antonio
  • IMA Clinical Research San Antonio - San Antonio
  • Dynamed Clinical Research, LP d/b/a DM Clinical Research - Sugar Land
  • DM Clinical Research - Tomball
  • Dynamed Clinical Research, LP d/b/a DM Clinical Research - Tomball

Florida

  • Alliance for Multispecialty Research, LLC - Doral
  • Indago Research & Health Center, Inc - Hialeah

Tennessee

  • AMR Clinical - Knoxville
  • AMR Clinical - Knoxville

Georgia

  • Clinical Research Atlanta - Stockbridge

Illinois

  • Optimal Research - Peoria

Louisiana

  • Alliance for Multispecialty Research, LLC - New Orleans

Michigan

  • Headlands Research - Detroit - Southfield

New York

  • Rochester Clinical Research, LLC - Rochester

Trial Details

FieldValue
Enrollment Target 558 participants
Start Date 2023-12-20
Est. Completion 2026-05-23
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06182124

The ClinicalTrials.gov registry entry for NCT06182124 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 401-participant average among 3 other Pneumococcal Disease trials with a reported enrollment target (39% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pneumococcal Disease appearing as the primary indexed condition, and to 5 interventions - of which 20-valent pneumococcal conjugate vaccine (20vPnC) is the first listed.

NCT06182124 reports 18 study locations spanning 10 distinct geographic areas - top geographies include Texas, Florida, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06182124 about?

NCT06182124 is a clinical study titled "A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults". The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease. This study will happen in 4 stages: Stage 1 is seeking participants who are between 18 years to 49 years ...

What is the current status of trial NCT06182124?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 558 participants. The study started on 2023-12-20. Estimated completion is 2026-05-23.

What conditions does trial NCT06182124 study?

This clinical trial studies the following conditions: Pneumococcal Disease.

What interventions are being tested in trial NCT06182124?

The interventions under investigation include: 20-valent pneumococcal conjugate vaccine (20vPnC) (BIOLOGICAL), Multivalent Pneumococcal Vaccine - Formulation 1 (BIOLOGICAL), Multivalent Pneumococcal Vaccine - Formulation 2 (BIOLOGICAL), Licensed pneumococcal comparator vaccine (BIOLOGICAL), Multivalent Pneumococcal Vaccine - Formulation 3 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06182124?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06182124 being conducted?

This trial has 18 study locations across Florida, Georgia, Illinois, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pneumococcal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pneumococcal Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.